相关实验视频

Updated: Jan 9, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

在输注低亲缘关系尼克丁-4特异性CAR T细胞后的点/瘤外毒性

Liya Ma¹, Jian Wang², Jing Li³

¹School of Biomedical Engineering, School of Science & School of Marine Science and Technology, Harbin Institute of Technology, Shenzhen, Guangdong, China.

Molecular therapy : the journal of the American Society of Gene Therapy

|December 5, 2025

概括

尼克-4 CAR T 细胞疗法显示出有前途的结果,但可能导致点/瘤外的毒性. 仔细的风险评估对于开发安全有效的Nectin-4向细胞疗法至关重要.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
细胞疗法细胞疗法

背景情况:

在固体瘤中,nectin-4是抗体与药物合物的有前途标.
作为CAR T细胞点的Nectin-4的潜力在临床上尚未得到充分探索.
化学抗原受体 (CARs) 为癌症免疫疗法提供了一种新的方法.

研究的目的:

开发和评估用于固体瘤的Nectin-4向CAR T细胞.
评估一种新的Nectin-4 CAR T细胞疗法 (CT293) 的安全性和有效性.
为了描述与Nectin-4向治疗相关的点/瘤外毒性.

主要方法:

从菌体库中识别了nectin-4特异性抗体.
在体外和体外开发和测试CAR T细胞 (包括CT293).
进行了首次在人身上进行临床试验 (NCT06724835) 以评估CT293的安全性.
特征性毒性进展和管理策略.

主要成果:

与其他候选药物相比,CT293表现出优越的抗瘤活性和多功能性.
CT293,来自一种低亲和度抗体,避免与可溶性尼克-4结合.
该研究报告了一例CT293输液后的点/瘤外毒性病例 (皮肤病,口腔粘膜,胃肠道).

结论:

尼克-4是CAR T细胞治疗的可行的标,CT293显示出显著的潜力.
针对性/非瘤毒性是Nectin-4向性细胞疗法的一个关键考虑因素.
系统的风险评估对于安全开发Nectin-4向细胞疗法至关重要.

关键词:

汽车汽车汽车汽车尼克-4的使用方法细胞治疗疗法细胞治疗疗法仿制性抗原受体的仿制性抗原受体低亲和度是一种低亲和度.在目标上/瘤外.一个案例,一个案例.

更多相关视频

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...